about
Current perspectives in the treatment of resistant schizophreniaWhat does schizophrenia teach us about antipsychotics?Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study.Clozapine: Current perspective.A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.Drugs in development for the treatment of schizophrenia.A review of the use of clozapine levels to guide treatment and determine cause of death.Quantitative exploration of factors influencing psychotic disorder ailments in Nigeria.Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.Blood Pressure and Heart Rate Changes During Clozapine Treatment.Molecular docking based screening of GABA (A) receptor inhibitors from plant derivatives.Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study.Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission.Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects.Clinical aspects of super-refractory schizophrenia: a 6-month cohort observational study.Experience with risperidone long-acting injection: results of a naturalistic observation study.Distinguishing Between Treatment-Resistant and Non-Treatment-Resistant Schizophrenia Using Regional Homogeneity
P2860
Q24650594-0F881A84-CDC3-4502-87BF-F57CDC00BC91Q26823906-EE98C5E8-3D49-45FF-AEC8-3CD8993A2070Q33568876-F979AA35-D55E-4DAD-BC61-E5C04D7F6FAEQ34021447-602105B6-B511-4892-8E31-DAAA597FDCDFQ34224372-4A47E2C2-CDAF-4674-B144-882B2975DD5DQ37546125-9AA8F365-F752-43FB-957E-F99531E9CE51Q37983363-C0E7058A-5874-4445-B3E8-E018E30A62D5Q38631264-0415DD05-8CD2-4E3B-9AEA-ED4E6A39A88BQ38741061-573F8628-7278-4DA9-8364-D74D44218D8AQ38966498-C51B1E4C-CA00-4EF5-8B84-0D28D3DC75EBQ40674790-56740AAB-463A-4E43-8A45-28E5A3DD8AB1Q41732419-AF80F4ED-45F7-4AF7-B77B-4F1A91168F14Q41833495-C9BA5CD8-6BD2-4AB7-886E-01DDEDDE4D51Q44754229-F4C17E88-4ED1-43DB-B7BF-FCE48C02FF67Q46984979-DFE790C5-D0CB-4455-AC79-8391D4999653Q51908469-C44AE898-1FDD-4871-AF5D-451F387B63D7Q58799078-806A06AD-C324-44B7-8A07-4FE171D7D08B
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Refractory schizophrenia and atypical antipsychotics
@ast
Refractory schizophrenia and atypical antipsychotics
@en
type
label
Refractory schizophrenia and atypical antipsychotics
@ast
Refractory schizophrenia and atypical antipsychotics
@en
prefLabel
Refractory schizophrenia and atypical antipsychotics
@ast
Refractory schizophrenia and atypical antipsychotics
@en
P2860
P1476
Refractory schizophrenia and atypical antipsychotics
@en
P2093
D Duncan-McConnell
P2860
P304
P356
10.1177/026988110001400411
P407
P50
P577
2000-01-01T00:00:00Z